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Background: Cerebral palsy is currently one of the major diseases that cause severe paralysis of the nervous system
in children; approximately 9–30% of cerebral palsy patients are also visually impaired, for which no effective
treatment is available. Bone marrow mesenchymal stem cells (BMSCs) have very strong self-renewal, proliferation,
and pluripotent differentiation potentials. Therefore, autologous BMSC transplantation has become a novel method
for treating cerebral palsy.
Methods: An 11-year-old boy had a clear history of dystocia and asphyxia after birth; at the age of 6 months, the
family members observed that his gaze roamed and noted that he displayed a lack of attention. A brain MRI
examination at the age of 7 years showed that the child had cerebral palsy with visual impairment (i.e., posterior
visual pathway injury). The patient was hospitalized for 20 days and was given four infusions of intravenous
autologous BMSCs. Before transplantation and 1, 6, and 12 months after transplantation, a visual evoked potential
test, an electrocardiogram, routine blood tests, and liver and kidney function tests were performed.
Results: The patient did not have any adverse reactions during hospitalization or postoperative follow-up. After
discharge, the patient could walk more smoothly than he could before transplantation; furthermore, his vision
significantly improved 6 months after transplantation, which was also supported by the electrophysiological
examinations.
Conclusions: The clinical application of BMSCs is effective for improving vision in a patient with cerebral palsy
combined with visual impairment.Background
This case study represents a typical case of cerebral palsy
combined with visual impairment. With medical
advances, the active treatment of preterm infants, chil-
dren with dystocia, and children with encephalitis or
hypoxic-ischemic encephalopathy results in significant
increases in the survival rates of these patients; however,
compared to normal infants, these patients have signifi-
cantly increased incidences of periventricular white mat-
ter demyelination. Many regions of the brain play* Correspondence: riveran@163.com
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reproduction in any medium, provided the orimportant roles in the generation of vision, such as the
cerebral cortex, the white matter, and the basal ganglia
[1-3]. During the perinatal period, most cerebral palsy
patients have a history of intrauterine hypoxia, preterm
birth, dystocia, asphyxia after birth, kernicterus, or other
complications. These factors can all result in impaired
function of the visual areas of the brain, which currently
has no effective treatment.Methods
Ethics
Prior to stem cell therapy, a consent form was signed by
the guardians of the patient. This study was approved by
the ethics committee of our hospital.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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General information
The patient, an 11-year-old boy, was admitted to our
hospital mainly due to “binocular vision disorders that
had lasted more than 11 years”. The patient was born
full-term with dystocia and had a history of significant
asphyxia, which improved after symptomatic treatment.
At the age of 6 months, his family members found that
he had trouble concentrating and following objects as
well as easy irritability and hyperactivity. A brain MRI
performed at the age of 7 showed cerebral hypoplasia
and optic nerve atrophy. The diagnosis was cerebral
palsy with visual impairment. He could not see and had
no light perception before he was 8 years old. At the age
of 8, the patient started to have light perception, and he
could only see objects 20 cm in front of him at the age
of 9; after that, his vision did not improve. When admit-
ted to our hospital, the physical examination revealed
that the patient presented with stuttering, a right-eye
visual acuity of 30 cm, and a left-eye visual acuity of 20
cm. The pupils were equal and round with diameters of
3 mm; the eyes were sensitive to light reflection, the
movements of both eyes were normal, strabismus was
absent, horizontal nystagmus was present, and eye clos-
ure was effective. The bilateral finger muscle strength
was grade 4, the right lower limb muscle tension was
grade 1, the tendon reflexes were active, and the bilateral
Chaddock’s sign was (+).Auxiliary examination
A brain MRI examination revealed bilateral parietal-
occipital lobe and corpus callosum dysplasia (Figure 1).
Ocular fundus examination: A leopard-spot-like fun-
dus was observed, the boundary of the optic disc was
clear, the color of the temporal disc border was light, theFigure 1 Brain MRI showed the bilateral parietal-occipital lobe and coC/D was 0.5–0.6 (normal cup to disc ratio: <0.3), and
the fovea reflex was (−).Visual evoked potential (VEP) (2010-10-22)
Flash stimulation tests were performed on both eyes.
The results revealed that the waveforms of both eyes
were poorly differentiated, the fundus was slightly wider
than normal, and the P100 latency was basically normal
(Figure 2).Intervention measures
Stem cell source
Bone marrow was collected from the patient. All tests
were normal, including blood leukocytes; lymphocytes;
liver function (aspartate aminotransferase, alanine ami-
notransferase, alkaline phosphatase, lactate dehydrogen-
ase, and hydroxybutyrate dehydrogenase); renal function
(uric acid, creatinine, β2-microglobulin, and α1 micro-
globulin); blood sugar; and blood lipids. The patient did
not have syphilis, HIV, hepatitis B, or hepatitis C infec-
tion, and there was no history of familial or hereditary
diseases.BMSC culture
Bone marrow was collected from the posterior superior
iliac spine. Sixty microliters of bone marrow was
extracted, and mononuclear cells in the bone marrow
were separated using density gradient centrifugation. Cells
were then inoculated into 100 ml flasks at a concentration
of 3× 105 cells/ml in α-MEM containing 10% FBS. Cells
were passaged when the cell density was above 90%. Cells
were collected at the 5th generation and were used for
transplantation by intravenous infusion.rpus callosum dysplasia.
Figure 2 Visual evoked potential on Oct. 22, 2010: Flash stimulation tests were performed on both eyes. The results revealed that the
waveforms of both eyes were poorly differentiated, the fundus was slightly wider than normal; P100 amplitude was lower than normal (T6- CZ),
but the P100 latency was basically normal.
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Prior to clinical application, multiple tests were per-
formed on the stem cells, including (1) cell morphology,
(2) cell surface marker detection, (3) bacterial detection,
(4) mycoplasma detection, and (5) endotoxin detection.
Clinical session of treatment
At each treatment session, the stem cells were fully dis-
persed and mixed using 100 ml normal saline, and then
4 × 107 cells were intravenously infused. Four infusions
were performed in each session, and the interval be-
tween two infusions was 7 days. After each time infu-
sion, the patient was monitored for vital signs including
blood pressure, heart rate, blood oxygen, and respiration
over 24 hours. Immunosuppressants were not adminis-
tered throughout the treatment period.
Monitoring of the clinical response in the patient
Blood leukocytes, lymphocytes, liver function, and kid-
ney function were monitored before transplantation and
1, 3, 6, and 12 months following.
Results
Detection of BMSC quality
(1) Cell morphology—The cells showed typical BMSC
morphology and strong growth under a phase-contrast
microscope. (2) Cell surface marker detection: CD44 and
CD29 positive rates were greater than 95%; the CD106
positive rate was greater than 80%; and the CD34, CD45,
CD14, and HLA-DR expression rates were less than 5%
(Figure 3). (3) Bacterial detection was negative. (4) Myco-
plasma was negative. (5) Endotoxin results were negative
as determined using limulus reagents (according to the
bacterial endotoxin and bacterial endotoxin application
guidelines of Chinese Pharmacopoeia, 2000 edition).Monitoring of adverse reactions after transplantation
After one session of stem cell transplantation and at 1,
3, 6, and 12 months after transplantation, the patient did
not have any side effects or complications; all test results
were within normal limits, and all vital signs were stable.
A physical examination 1 year after transplantation
(2011-10-12) revealed that the patient had a right-eye
visual acuity of 1 m and a left-eye visual acuity of 80 cm.
The right lower limb muscle tension was significantly
decreased compared to that before transplantation, and
the patient had heel contact with the ground and walked
more smoothly than before transplantation. The auxil-
iary examinations were performed 1 year after trans-
plantation (2011-10-12); the VEP results showed that the
waveforms of both eyes were well differentiated, the fun-
dus was slightly wider, and the P100 latency was essen-
tially normal when flash stimulation tests were
performed on both eyes (Figure 4).
Conclusion
The classic visual pathway contains two parts. The first
part is the anterior visual pathway, which refers to the
visual pathways below the lateral geniculate nucleus, in-
cluding receptors, bipolar cells, ganglion cells, the optic
nerve, the optic chiasm, the optic tract, and the lateral
geniculate body. The second part is the posterior visual
pathway, which refers to the visual pathway posterior to
the lateral geniculate body, including the optic radiation,
the subcortical area, and the visual cortex. The patient
in this study had a posterior visual pathway injury,
which was based on (1) normal pupillary light reflex; (2)
fundus examination, which showed no obvious optic at-
rophy; (3) eye examination, which showed no positive
signs; (4) VEP after flash stimulation of both eyes, which
showed poor bilateral waveform differentiation and a
Figure 3 BMSC surface marker detection: CD44 and CD29 positive rates were greater than 95%, the CD106 positive rate was greater
than 80%, and the CD34, CD45, CD14, and HLA-DR expression rates were less than 5%.
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plasia of the bilateral parietal-occipital lobe and the cor-
pus callosum. Posterior visual pathway injuries are
commonly observed in cerebral contusions of the occipi-
tal lobe and in diffused brain injuries, such as brain ede-
mas and hernias; these injuries are usually accompanied
by signs of nervous system damage. In addition to visual
injuries, this patient had limb movement disorders.
BMSCs have very strong self-renewal, proliferation,
and pluripotent differentiation capabilities. Under differ-
ent induction conditions, BMSCs can differentiate intomany types of cells in vitro, such as bone cells, cartilage
cells, fat cells, tendons, and muscle cells. BMSCs have
many advantages; they are easy to obtain and amplify
in vitro, are unlikely to cause immune rejection after
transplantation in vivo, and present no ethical contro-
versy. Recent studies have also indicated that BMSCs
can be induced into neuron-like cells and glial cells both
in vivo and in vitro [4-6] and can differentiate into visual
receptors and glial cells in the ganglion [7,8]. Many stud-
ies have evaluated the treatment of cerebral infarctions
[9] and traumatic brain injuries using BMSCs; however,
Figure 4 Visual evoked potential on Oct. 12, 2011: Flash stimulation tests were performed on both eyes. The VEP results showed that the
waveforms of both eyes were well differentiated, the fundus was slightly wider, P100 amplitude increased obviously and the P100 latency was
essentially normal.
Li et al. Journal of Translational Medicine 2012, 10:100 Page 5 of 7
http://www.translational-medicine.com/content/10/1/100studies on hypoxic-ischemic encephalopathy have just
begun. In some studies, BMSCs were intravenously
transplanted into newborn rats with hypoxic-ischemic
encephalopathy; the characteristics of transplanted stem
cells could be detected in rat brains, indicating that stem
cells can pass through the blood–brain barrier. In
addition, these cells can survive at the sites of injury.
The specific mechanism may involve several factors.
First, the process of stem cells passing through the
blood–brain barrier may be a specific transfer process
mediated by endothelial cell adhesion molecules in the
blood–brain barrier [10]. Second, after brain tissue in-
jury, the blood–brain barrier is damaged, thus increasing
permeability [11]. Third, injured tissues possess chemo-
taxis functions [12]. Finally, cerebral ischemia can in-
duce the expression of neurotrophic factors around the
ischemic zone, which is favorable for cell survival [13].
In this study, the characteristics of surface antigens on
cultured stem cells were detected using flow cytometry.
The results showed that the expression levels of CD44,
CD29, CD54, and CD106 were high in nuclear cells
(with expression rates of 98.72%, 90.71%, 92.5%, and
40.81%, respectively). In contrast, the cells were negative
for CD45, CD34, HLA-DR, and CD14 expression (<5%
expression). In BMSC studies, CD9, CD29, CD44, CD71,
CD90, and CD106 are recognized as important surface
markers of BMSCs, while the hematopoietic stem cell
marker antigen CD3, the leukocyte marker antigen
CD45, and the monocyte/macrophage surface antigen
CD14 are not expressed [14,15]. CD45 is an important
surface marker of MSCs [16]; it can mediate cell-cell
and cell-extracellular matrix interactions and participate
in the growth, maturation, and differentiation of MSCs.
CD44 regulates the differentiation, fusion, and migration-
specific adhesion of MSCs, thus providing anchorage-
dependent growth sites for CD44-expressing MSCs. The
cultured stem cells in this study were MSCs.The mechanism underlying the function of stem cell
transplantation in nerve repair is still not very clear.
There are two general hypotheses: cell replacement
function and neurotrophic effect. Therefore, many
researchers are trying different methods to induce the
differentiation of BMSCs into essential neuron-like cells
for transplantation; they believe that this strategy could
enable the transplanted stem cells to fully replace the
damaged cells; however, from the viewpoint of neuro-
trophic hypothesis, pure neuron-like cells might not
maximally perform the required function. We believe
that the transplanted cells should not be too pure; they
should consist of a mixture of a few cell types. Some
cells could perform nerve repair through cell replace-
ment, while other cells could secrete different cytokines
to assist in nerve repair and regeneration, thus support-
ing the growth of neural stem cells and inducing differ-
entiation [17]. Therefore, we used BMSCs without
inducing any specific differentiation and performed the
transplantation using intravenous fusion, which is a safe
and simple method.
One year after receiving one session of BMSC trans-
plantation, the patient described in this study showed
significant improvement based on his symptoms, physical
examinations, and electrophysiological studies. The phys-
ical examination results revealed that the right-eye visual
acuity was 100 cm and the left-eye visual acuity was
80 cm. The right lower limb muscle tension was signifi-
cantly decreased compared to the pre-surgical measure-
ment, and the patient walked more smoothly than
previously; the VEP was close to normal. During the
treatment and at regular follow-ups at 3, 6, and
12 months post-transplant, the patient did not exhibit
fever, headache, blood pressure fluctuations, arrhythmias,
or other symptoms of discomfort without an obvious rea-
son. During the period of stem cell transplantation, the
patient did not use any neurotrophic drugs or drugs that
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baric oxygen therapy or participate in functional rehabili-
tation exercises. Of course, we cannot completely rule
out the possibility that the patient self-recovered; how-
ever, it is difficult to attribute these improvements to
self-recovery, as his vision did not improve significantly
in the two years prior to transplantation but improved
rapidly within 1 year after stem cell transplantation.
Therefore, we have reason to believe that it was stem cell
therapy that promoted the recovery of his vision.
The mechanism that BMSCs use to repair the nerve
damage may involve the nutritional effect of the neuro-
trophic factors (such as BDNF and NGF) released by
stem cells [18]. Research has shown that BMSCs can im-
prove neurotrophic factor expression, which may be the
key to promoting brain function recovery. Rat BMSCs
can continuously express NGF and BDNF when they are
cultured in vitro to the sixth generation [19,20]. In
addition, BMSCs can secrete a large amount of useful
cell factors, such as BDNF, that can promote B lympho-
cytes to increase the free calcium ion concentrations in
cells and thus improve their immune regulation and re-
sistance [21]. Mahmood [22] used BMSCs to treat rats
with brain injury and showed that the concentrations of
NGF and BDNF in the treatment group were signifi-
cantly higher than those in the control group; Addition-
ally, these rats still showed increased BDNF expression 3
months later. Furthermore, the mechanism may also in-
volve the induction of angiogenesis due to the release of
vascular endothelial growth factors that is promoted by
stem cells, thus improving blood circulation in the
injured regions [23], or a microenvironment that is fa-
vorable for the regeneration and repair of autologous
stem cells provided by exogenous stem cells, thus pro-
moting the proliferation and differentiation of autolo-
gous stem cells and repairing injured nerves. Of course,
these are only hypotheses; further confirmation through
basic experimental studies is needed.
The reason for the improvement in our patient’s symp-
toms 1 year after stem cell transplantation is unclear; it
is possible that in addition to the short-lasting effects
that occurred via the trophic support of MSCs, these
cells exhibited long-lasting effects [24,25]. One possible
explanation for the therapeutic mechanism of MSCs is
that they increase neurogenesis. Preclinical studies have
shown the importance of neurogenesis in an animal
model of stroke, and transplanted MSCs might enhance
this process [26-28]. Stroke-induced neurogenesis was
reported to continue for up to 1 year and to occur in
aged brains [29]. After several preclinical studies, Zhu
et al. [30] treated several patients by applying autologous
stem cells. These authors labeled neural stem cells from
humans with superparamagnetic iron oxide nanoparti-
cles and tracked these cells using magnetic resonanceimaging (MRI). They did not observe a hypointense sig-
nal after 7 weeks, and they attributed this result to a di-
lution of the signal due to cell proliferation. For several
reasons, including ethical concerns, it is difficult to ob-
serve stem cell survival in the human body. Currently,
the only way to judge cell survival is by an improvement
in the symptoms of the treated patients.
In summary, BMSC transplantation can be used to ef-
fectively treat cerebral palsy combined with visual im-
pairment. To a certain extent, it can improve limb
movement disorders and visual impairment caused by
posterior visual pathway injury.
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